-
1
-
-
40849147041
-
EGFR antagonists in cancer treatment
-
Ciardiello F, Tortora G EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
-
(2008)
N Engl J Med
, vol.358
, pp. 1160-1174
-
-
Ciardiello, F.1
Tortora, G.2
-
2
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
3
-
-
53249123419
-
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study
-
Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008, 14:5869-5876.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5869-5876
-
-
Personeni, N.1
Fieuws, S.2
Piessevaux, H.3
-
4
-
-
73349094741
-
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
-
Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27:5924-5930.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5924-5930
-
-
Laurent-Puig, P.1
Cayre, A.2
Manceau, G.3
-
5
-
-
17844362179
-
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
-
Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279-286.
-
(2005)
Lancet Oncol
, vol.6
, pp. 279-286
-
-
Moroni, M.1
Veronese, S.2
Benvenuti, S.3
-
6
-
-
34548258303
-
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
-
Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007, 25:3238-3245.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3238-3245
-
-
Sartore-Bianchi, A.1
Moroni, M.2
Veronese, S.3
-
7
-
-
73349098041
-
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab
-
Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009, 27:5068-5074.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5068-5074
-
-
Jacobs, B.1
De Roock, W.2
Piessevaux, H.3
-
8
-
-
77949887855
-
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study
-
Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010, 28:1181-1189.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1181-1189
-
-
Tabernero, J.1
Cervantes, A.2
Rivera, F.3
-
9
-
-
34548238762
-
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
-
Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25:3230-3237.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3230-3237
-
-
Khambata-Ford, S.1
Garrett, C.R.2
Meropol, N.J.3
-
10
-
-
77955604846
-
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
-
Perkins G, Lièvre A, Ramacci C, et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer 2010, 127:1321-1331.
-
(2010)
Int J Cancer
, vol.127
, pp. 1321-1331
-
-
Perkins, G.1
Lièvre, A.2
Ramacci, C.3
-
11
-
-
65349189958
-
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
-
Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2091-2096
-
-
Allegra, C.J.1
Jessup, J.M.2
Somerfield, M.R.3
-
12
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
-
De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
-
13
-
-
57449095367
-
BRAF wild-type is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
Di Nicolantonio F, Martini M, Molinari F, et al. BRAF wild-type is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5705-5712
-
-
Di Nicolantonio, F.1
Martini, M.2
Molinari, F.3
-
14
-
-
77955266489
-
Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome
-
abstr 3570.
-
Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. Proc Am Soc Clin Oncol 2010, 28. abstr 3570.
-
(2010)
Proc Am Soc Clin Oncol
, vol.28
-
-
Van Cutsem, E.1
Lang, I.2
Folprecht, G.3
-
15
-
-
62449302407
-
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
-
Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857.
-
(2009)
Cancer Res
, vol.69
, pp. 1851-1857
-
-
Sartore-Bianchi, A.1
Martini, M.2
Molinari, F.3
-
16
-
-
65649086786
-
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
-
Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009, 15:3184-3188.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3184-3188
-
-
Prenen, H.1
De Schutter, J.2
Jacobs, B.3
-
17
-
-
35348908314
-
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
-
Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97:1139-1145.
-
(2007)
Br J Cancer
, vol.97
, pp. 1139-1145
-
-
Frattini, M.1
Saletti, P.2
Romagnani, E.3
-
18
-
-
66849140563
-
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
-
Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009, 27:2622-2629.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2622-2629
-
-
Loupakis, F.1
Pollina, L.2
Stasi, I.3
-
19
-
-
77949435827
-
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
-
Bardelli A, Siena S Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1254-1261
-
-
Bardelli, A.1
Siena, S.2
-
20
-
-
0028074316
-
Phosphatidylinositol-3-OH kinase as a direct target of Ras
-
Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532.
-
(1994)
Nature
, vol.370
, pp. 527-532
-
-
Rodriguez-Viciana, P.1
Warne, P.H.2
Dhand, R.3
-
21
-
-
58249089525
-
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
-
Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58:90-96.
-
(2009)
Gut
, vol.58
, pp. 90-96
-
-
Ogino, S.1
Nosho, K.2
Kirkner, G.J.3
-
22
-
-
0033739215
-
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study
-
Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000, 9:1193-1197.
-
(2000)
Cancer Epidemiol Biomarkers Prev
, vol.9
, pp. 1193-1197
-
-
Samowitz, W.S.1
Curtin, K.2
Schaffer, D.3
Robertson, M.4
Leppert, M.5
Slattery, M.L.6
-
23
-
-
33646228635
-
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
-
Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
-
(2006)
Cancer Res
, vol.66
, pp. 3992-3995
-
-
Lièvre, A.1
Bachet, J.B.2
Le Corre, D.3
-
24
-
-
78049341541
-
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010, 304:1812-1820.
-
(2010)
JAMA
, vol.304
, pp. 1812-1820
-
-
De Roock, W.1
Jonker, D.J.2
Di Nicolantonio, F.3
-
25
-
-
63149194964
-
V600E BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
-
Pratilas CA, Taylor BS, Yeb Q, et al. V600E BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009, 106:4519-4524.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 4519-4524
-
-
Pratilas, C.A.1
Taylor, B.S.2
Yeb, Q.3
-
26
-
-
79957488015
-
-
DUSP expression as a predictor of outcome after cetuximab treatment in Kras wild-type and mutant colorectal tumors. Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology; San Francisco, CA, USA; Jan 22-24, 2010. Abstract 289.
-
De Roock W, Fieuws S, Biesmans B, et al. DUSP expression as a predictor of outcome after cetuximab treatment in Kras wild-type and mutant colorectal tumors. Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology; San Francisco, CA, USA; Jan 22-24, 2010. Abstract 289.
-
-
-
De Roock, W.1
Fieuws, S.2
Biesmans, B.3
-
27
-
-
22244472992
-
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
-
Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005, 65:6063-6069.
-
(2005)
Cancer Res
, vol.65
, pp. 6063-6069
-
-
Samowitz, W.S.1
Sweeney, C.2
Herrick, J.3
-
28
-
-
75749102647
-
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
-
Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28:466-474.
-
(2010)
J Clin Oncol
, vol.28
, pp. 466-474
-
-
Roth, A.D.1
Tejpar, S.2
Delorenzi, M.3
-
29
-
-
79957459729
-
-
Use of massively parallel, next-generation sequencing to identify gene mutations beyond KRAS that predict response to panitumumab in a randomized phase III monotherapy study of metastatic colorectal cancer. American Association for Cancer Research Annual Meeting; Washington, DC, USA; April 17-21, 2010. Abstract 174.
-
Peeters M, Oliner KS, Parker A, et al. Use of massively parallel, next-generation sequencing to identify gene mutations beyond KRAS that predict response to panitumumab in a randomized phase III monotherapy study of metastatic colorectal cancer. American Association for Cancer Research Annual Meeting; Washington, DC, USA; April 17-21, 2010. Abstract 174.
-
-
-
Peeters, M.1
Oliner, K.S.2
Parker, A.3
-
30
-
-
77951945506
-
Status of PI3K inhibition and biomarker development in cancer therapeutics
-
Markman B, Atzori F, Perez-Garci{dotless}a J, Tabernero J, Baselga J Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010, 21:683-691.
-
(2010)
Ann Oncol
, vol.21
, pp. 683-691
-
-
Markman, B.1
Atzori, F.2
Perez-Garcia, J.3
Tabernero, J.4
Baselga, J.5
-
31
-
-
44449133319
-
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations
-
Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008, 10:534-541.
-
(2008)
Neoplasia
, vol.10
, pp. 534-541
-
-
Nosho, K.1
Kawasaki, T.2
Ohnishi, M.3
-
32
-
-
42149083899
-
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signalling network correlate with poor survival in a population-based series of colon cancers
-
Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signalling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008, 122:2255-2259.
-
(2008)
Int J Cancer
, vol.122
, pp. 2255-2259
-
-
Barault, L.1
Veyrie, N.2
Jooste, V.3
-
33
-
-
70350028742
-
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer
-
Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009, 4:7287.
-
(2009)
PLoS One
, vol.4
, pp. 7287
-
-
Sartore-Bianchi, A.1
Di Nicolantonio, F.2
Nichelatti, M.3
-
34
-
-
40649096375
-
Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
-
Zhao L, Vogt PK Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008, 105:2652-2657.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 2652-2657
-
-
Zhao, L.1
Vogt, P.K.2
-
35
-
-
63049111794
-
PIK3CA mutation Is associated with poor prognosis among patients with curatively resected colon cancer
-
Ogino S, Katsuhiko N, Gregory J, et al. PIK3CA mutation Is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009, 27:1477-1484.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1477-1484
-
-
Ogino, S.1
Katsuhiko, N.2
Gregory, J.3
-
36
-
-
35148885729
-
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
-
Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
-
(2007)
Cancer Cell
, vol.12
, pp. 395-402
-
-
Berns, K.1
Horlings, H.M.2
Hennessy, B.T.3
-
37
-
-
2342504508
-
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers
-
Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004, 64:3014-3021.
-
(2004)
Cancer Res
, vol.64
, pp. 3014-3021
-
-
Goel, A.1
Arnold, C.N.2
Niedzwiecki, D.3
-
38
-
-
5144226211
-
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
-
Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
-
(2004)
Cancer Cell
, vol.6
, pp. 117-127
-
-
Nagata, Y.1
Lan, K.H.2
Zhou, X.3
-
39
-
-
68949201629
-
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
-
Gazdar AF Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28:24.
-
(2009)
Oncogene
, vol.28
, pp. 24
-
-
Gazdar, A.F.1
-
40
-
-
19944422060
-
Somatic mutations of EGFR in colorectal cancers and glioblastomas
-
Barber TD, Vogelstein B, Kinzler KW, Velculescu VE Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004, 351:2883.
-
(2004)
N Engl J Med
, vol.351
, pp. 2883
-
-
Barber, T.D.1
Vogelstein, B.2
Kinzler, K.W.3
Velculescu, V.E.4
-
41
-
-
25144476901
-
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
-
Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005, 11:6650-6656.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6650-6656
-
-
Ogino, S.1
Meyerhardt, J.A.2
Cantor, M.3
-
42
-
-
70350653741
-
Nuclear EGFR contributes to acquired resistance to cetuximab
-
Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009, 28:3801-3813.
-
(2009)
Oncogene
, vol.28
, pp. 3801-3813
-
-
Li, C.1
Iida, M.2
Dunn, E.F.3
Ghia, A.J.4
Wheeler, D.L.5
-
43
-
-
34250898667
-
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt
-
Yamasaki F, Johansen MJ, Zhang D, et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007, 67:5779-5788.
-
(2007)
Cancer Res
, vol.67
, pp. 5779-5788
-
-
Yamasaki, F.1
Johansen, M.J.2
Zhang, D.3
-
44
-
-
19944427176
-
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
-
Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004, 11:793-814.
-
(2004)
Endocr Relat Cancer
, vol.11
, pp. 793-814
-
-
Jones, H.E.1
Goddard, L.2
Gee, J.M.3
-
45
-
-
0037110602
-
Overexpression of the insulin-like growth factor I receptor in human colon carcinomas
-
Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D, Baretton GB Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 2002, 95:2086-2095.
-
(2002)
Cancer
, vol.95
, pp. 2086-2095
-
-
Weber, M.M.1
Fottner, C.2
Liu, S.B.3
Jung, M.C.4
Engelhardt, D.5
Baretton, G.B.6
-
46
-
-
54249155585
-
Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor
-
Hu YP, Patil SB, Panasiewicz M, et al. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res 2008, 68:8004-8013.
-
(2008)
Cancer Res
, vol.68
, pp. 8004-8013
-
-
Hu, Y.P.1
Patil, S.B.2
Panasiewicz, M.3
-
47
-
-
77955856575
-
Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan
-
abstr 4017.
-
Scartozzi M, Bearzi I, Mandolesi A, et al. Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan. Proc Am Soc Clin Oncol 2009, 27. abstr 4017.
-
(2009)
Proc Am Soc Clin Oncol
, vol.27
-
-
Scartozzi, M.1
Bearzi, I.2
Mandolesi, A.3
-
48
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
-
(2007)
Science
, vol.316
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
-
49
-
-
56449089812
-
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
-
Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68:9479-9487.
-
(2008)
Cancer Res
, vol.68
, pp. 9479-9487
-
-
Yano, S.1
Wang, W.2
Li, Q.3
-
50
-
-
0037386758
-
C-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases
-
Takeuchi H, Bilchik A, Saha S, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003, 9:1480-1488.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1480-1488
-
-
Takeuchi, H.1
Bilchik, A.2
Saha, S.3
-
51
-
-
52449122415
-
The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer
-
Ginty F, Adak S, Can A, et al. The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res 2008, 14:3814-3822.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3814-3822
-
-
Ginty, F.1
Adak, S.2
Can, A.3
-
52
-
-
33847326735
-
Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome
-
Kammula US, Kuntz EJ, Francone TD, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007, 248:219-228.
-
(2007)
Cancer Lett
, vol.248
, pp. 219-228
-
-
Kammula, U.S.1
Kuntz, E.J.2
Francone, T.D.3
-
53
-
-
0037358220
-
Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo
-
Long IS, Han K, Li M, et al. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. Mol Cancer Res 2003, 1:393-401.
-
(2003)
Mol Cancer Res
, vol.1
, pp. 393-401
-
-
Long, I.S.1
Han, K.2
Li, M.3
-
54
-
-
0037105707
-
Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer
-
Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 2002, 62:5126-5128.
-
(2002)
Cancer Res
, vol.62
, pp. 5126-5128
-
-
Boon, E.M.1
van der Neut, R.2
van de Wetering, M.3
Clevers, H.4
Pals, S.T.5
-
55
-
-
0037905558
-
Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells
-
Herynk MH, Stoeltzing O, Reinmuth N, et al. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res 2003, 63:2990-2996.
-
(2003)
Cancer Res
, vol.63
, pp. 2990-2996
-
-
Herynk, M.H.1
Stoeltzing, O.2
Reinmuth, N.3
-
56
-
-
0036251746
-
Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery
-
Lee JC, Wang ST, Chow NH, Yang HB Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002, 38:1065-1071.
-
(2002)
Eur J Cancer
, vol.38
, pp. 1065-1071
-
-
Lee, J.C.1
Wang, S.T.2
Chow, N.H.3
Yang, H.B.4
-
57
-
-
0037012008
-
Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells
-
Venkateswarlu S, Dawson DM, St Clair P, Gupta A, Willson JK, Brattain MG Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 2002, 21:78-86.
-
(2002)
Oncogene
, vol.21
, pp. 78-86
-
-
Venkateswarlu, S.1
Dawson, D.M.2
St Clair, P.3
Gupta, A.4
Willson, J.K.5
Brattain, M.G.6
-
58
-
-
79957508906
-
-
Heregulin as a novel resistant factor for cetuximab. American Association for Cancer Research 101st Annual Meeting; Washington, DC, USA; April 17-21, 2010. Abstract 3733.
-
Yonesaka K, Okamoto I, Satoh T, et al. Heregulin as a novel resistant factor for cetuximab. American Association for Cancer Research 101st Annual Meeting; Washington, DC, USA; April 17-21, 2010. Abstract 3733.
-
-
-
Yonesaka, K.1
Okamoto, I.2
Satoh, T.3
-
59
-
-
52649143725
-
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
-
Bianco R, Rosa R, Damiano V, et al. Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 2008, 14:5069-5080.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5069-5080
-
-
Bianco, R.1
Rosa, R.2
Damiano, V.3
-
60
-
-
47549092230
-
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
-
Barr S, Thomson S, Buck E, et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 2008, 25:685-693.
-
(2008)
Clin Exp Metastasis
, vol.25
, pp. 685-693
-
-
Barr, S.1
Thomson, S.2
Buck, E.3
-
61
-
-
57049132745
-
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
-
Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 2008, 25:843-854.
-
(2008)
Clin Exp Metastasis
, vol.25
, pp. 843-854
-
-
Thomson, S.1
Petti, F.2
Sujka-Kwok, I.3
Epstein, D.4
Haley, J.D.5
-
62
-
-
0141838134
-
Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids
-
Bates RC, Goldsmith JD, Bachelder RE, et al. Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol 2003, 13:1721-1727.
-
(2003)
Curr Biol
, vol.13
, pp. 1721-1727
-
-
Bates, R.C.1
Goldsmith, J.D.2
Bachelder, R.E.3
-
63
-
-
29344465338
-
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients
-
Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005, 11:8686-8698.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 8686-8698
-
-
Yauch, R.L.1
Januario, T.2
Eberhard, D.A.3
-
64
-
-
0034735754
-
Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts
-
De Luca A, Arra C, D'Antonio A, et al. Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene 2000, 19:5863-5871.
-
(2000)
Oncogene
, vol.19
, pp. 5863-5871
-
-
De Luca, A.1
Arra, C.2
D'Antonio, A.3
-
65
-
-
68949086867
-
Targeting the RAF-MEK-ERK pathway in cancer therapy
-
Montagut C, Settleman J Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009, 283:125-134.
-
(2009)
Cancer Lett
, vol.283
, pp. 125-134
-
-
Montagut, C.1
Settleman, J.2
-
66
-
-
31144453233
-
BRAF mutation predicts sensitivity to MEK inhibition
-
Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
-
(2006)
Nature
, vol.439
, pp. 358-362
-
-
Solit, D.B.1
Garraway, L.A.2
Pratilas, C.A.3
-
67
-
-
42649125571
-
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
-
Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008, 40:600-608.
-
(2008)
Nat Genet
, vol.40
, pp. 600-608
-
-
Haigis, K.M.1
Kendall, K.R.2
Wang, Y.3
-
68
-
-
42949149240
-
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
-
Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008, 105:3041-3046.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 3041-3046
-
-
Tsai, J.1
Lee, J.T.2
Wang, W.3
-
69
-
-
78649723255
-
PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors
-
abstr 3534.
-
Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. Proc Am Soc Clin Oncol 2010, 28. abstr 3534.
-
(2010)
Proc Am Soc Clin Oncol
, vol.28
-
-
Kopetz, S.1
Desai, J.2
Chan, E.3
-
70
-
-
66149126085
-
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression
-
Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 2009, 69:3042-3051.
-
(2009)
Cancer Res
, vol.69
, pp. 3042-3051
-
-
Hoeflich, K.P.1
Herter, S.2
Tien, J.3
-
71
-
-
77949685981
-
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
-
Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
-
(2010)
Nature
, vol.464
, pp. 431-435
-
-
Hatzivassiliou, G.1
Song, K.2
Yen, I.3
-
72
-
-
33749430399
-
Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner
-
Skeen JE, Bhaskar PT, Chen C-C Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 2006, 10:269-280.
-
(2006)
Cancer Cell
, vol.10
, pp. 269-280
-
-
Skeen, J.E.1
Bhaskar, P.T.2
Chen, C.-C.3
-
73
-
-
32944457518
-
MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
-
O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
-
(2006)
Cancer Res
, vol.66
, pp. 1500-1508
-
-
O'Reilly, K.E.1
Rojo, F.2
She, Q.B.3
-
74
-
-
66249116702
-
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
-
Wee S, Jagani Z, Xiang KX, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009, 69:4286-4293.
-
(2009)
Cancer Res
, vol.69
, pp. 4286-4293
-
-
Wee, S.1
Jagani, Z.2
Xiang, K.X.3
-
75
-
-
51349164790
-
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
-
Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074.
-
(2008)
J Clin Invest
, vol.118
, pp. 3065-3074
-
-
Carracedo, A.1
Ma, L.2
Teruya-Feldstein, J.3
-
76
-
-
63349097231
-
Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer
-
Zhang YJ, Tian XQ, Sun DF, Zhao SL, Xiong H, Fang JY Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Invest 2009, 27:273-285.
-
(2009)
Cancer Invest
, vol.27
, pp. 273-285
-
-
Zhang, Y.J.1
Tian, X.Q.2
Sun, D.F.3
Zhao, S.L.4
Xiong, H.5
Fang, J.Y.6
-
77
-
-
57349194139
-
Effective use of PI3K and MEK inhibitors to treat mutant KRAS G12D and PIK3CA H1047R murine lung cancers
-
Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant KRAS G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
-
(2008)
Nat Med
, vol.14
, pp. 1351-1356
-
-
Engelman, J.A.1
Chen, L.2
Tan, X.3
-
78
-
-
58349091262
-
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
-
Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009, 69:565-572.
-
(2009)
Cancer Res
, vol.69
, pp. 565-572
-
-
Mirzoeva, O.K.1
Das, D.2
Heiser, L.M.3
-
79
-
-
77955288855
-
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
-
Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010, 120:2858-2866.
-
(2010)
J Clin Invest
, vol.120
, pp. 2858-2866
-
-
Di Nicolantonio, F.1
Arena, S.2
Tabernero, J.3
|